Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 109 results for melanoma

  1. Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]

    Discontinued Reference number: GID-TA10627

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)

    Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA904

  3. Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]

    Awaiting development Reference number: GID-TA11275 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)

    Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults.

    Technology appraisal guidance
    Published
    11 January 2023
    View recommendations

    Sections for TA857

  5. Nivolumab for previously treated advanced renal cell carcinoma (TA417)

    Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA417

  6. Further research into whether concomitant dacarbazine enhances the clinical effectiveness of ipilimumab would be encouraged because it could provide information for future treatment strategies, as would more data on the relative effectiveness of ipilimumab when given as a first-line or second-line treatment.

    Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma Number TA319 Date issued July 2014 Other details

    Research recommendation
    Published
    9 June 2015

  7. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.

    Technology appraisal guidance
    Published
    28 April 2021
    View recommendations

    Sections for TA692

  8. Surgical excision for people with lentigo maligna: For people with lentigo maligna (stage 0 in sun damaged skin, usually on the face) how effective is Mohs micrographic surgery, compared with excision with a 0.5 cm clinical margin, in preventing biopsy proven local recurrence at 5 years? This should be investigated in a randomised controlled trial. Secondary outcomes should include cosmetic and functional outcomes.

    adjacent skin. Source guidance details Comes from guidance Melanoma: assessment and management Number NG14 Date issued

    Research recommendation
    Published
    4 August 2022

  9. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued Reference number: GID-TAG479

    Technology appraisal guidance
    Discontinued

  10. Vandetanib for treating medullary thyroid cancer (TA550)

    Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.

    Technology appraisal guidance
    Published
    12 December 2018
    View recommendations

    Sections for TA550

  11. Cabozantinib for treating medullary thyroid cancer (TA516)

    Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer in adults.

    Technology appraisal guidance
    Published
    28 March 2018
    View recommendations

    Sections for TA516

  12. Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)

    Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA830

  13. Enzalutamide for the treatment of hormone refractory prostate cancer TA316

    Discontinued Reference number: GID-TA10267

    Technology appraisal guidance
    Discontinued

  14. Axxent electronic brachytherapy system for early stage breast cancer (MIB76)

    NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer

    Medtech innovation briefing
    Published
    24 August 2016

  15. Cemiplimab for treating advanced cutaneous squamous cell carcinoma (TA802)

    Evidence-based recommendations on cemiplimab (Libtayo) for metastatic or locally advanced cutaneous squamous cell carcinoma in adults.

    Technology appraisal guidance
    Published
    29 June 2022
    View recommendations

    Sections for TA802